Associate Professor Richard Haynes
- 3C: A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial
- ASCEND: A Study of Cardiovascular Events iN Diabetes
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D
- EMPA-KIDNEY: the study of heart and kidney protection with empagliflozin
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- Trials Methodology
- UK HARP III
Professor of Renal Medicine and Clinical Trials
- MRC Population Health Research Unit Programme Leader: Randomised Trials in Cardiovascular and Metabolic Disease
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he is now Programme Leader in the MRC Population Health Research Unit for the programme in Randomised Trials in Cardiovascular and Metabolic Disease.
Serious Adverse Effects of Extended-Release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Haynes R. et al, (2019), Clin Ther
Pathophysiology and management of monoclonal gammopathy of renal significance.
Jain A. et al, (2019), Blood Adv, 3, 2409 - 2423
Long term outcomes in monoclonal gammopathy of renal significance.
Khera A. et al, (2019), Br J Haematol
Chronic kidney disease, heart failure and neprilysin inhibition.
Haynes R. et al, (2019), Nephrol Dial Transplant
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I. et al, (2019), Kidney Int